INV 102 - Invirsa
Alternative Names: INV-102 InvirsaLatest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Invirsa
- Class Adenine nucleotides; Anti-infectives; Anti-inflammatories; Antivirals; Eye disorder therapies; Small molecules
- Mechanism of Action DNA repair enzyme stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic macular oedema; Dry eyes; Infectious keratoconjunctivitis
- No development reported Respiratory tract infections
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for research development in Respiratory-tract-infections in USA
- 07 Sep 2024 Phase-II clinical trials in Diabetic macular oedema in USA (Ophthalmic) (NCT06599684)
- 22 Aug 2024 Invirsa completes a phase II trial in Infectious keratoconjunctivitis in USA and Thailand (Ophthalmic) (NCT05636228)